Compare MPV & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPV | RPID |
|---|---|---|
| Founded | 1988 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.1M | 178.6M |
| IPO Year | N/A | 2021 |
| Metric | MPV | RPID |
|---|---|---|
| Price | $19.35 | $3.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 25.2K | ★ 104.8K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | N/A | ★ $30,523,000.00 |
| Revenue This Year | N/A | $19.36 |
| Revenue Next Year | N/A | $21.48 |
| P/E Ratio | $9.35 | ★ N/A |
| Revenue Growth | N/A | ★ 16.63 |
| 52 Week Low | $11.18 | $0.87 |
| 52 Week High | $16.42 | $4.50 |
| Indicator | MPV | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 40.48 | 39.83 |
| Support Level | $19.30 | $3.78 |
| Resistance Level | $20.21 | $4.07 |
| Average True Range (ATR) | 0.29 | 0.21 |
| MACD | -0.04 | -0.10 |
| Stochastic Oscillator | 5.36 | 23.65 |
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.